E3 ubiquitin-protein ligase TRIP12 (EC 2.3.2.26) (E3 ubiquitin-protein ligase for Arf) (ULF) (HECT-type E3 ubiquitin transferase TRIP12) (Thyroid receptor-interacting protein 12) (TR-interacting protein 12) (TRIP-12)
1_MSNRP 6_ NNNPG 11_ GSLRR 16_ SQRNT 21_ AGAQP 26_ QDDSI 31_ GGRSC 36_ SSSSA 41_ VIVPQ 46_ PEDPD 51_ RANTS 56_ ERQKT 61_ GQVPK 66_ KDNSR 71_ GVKRS 76_ ASPDY 81_ NRTNS 86_ PSSAK 91_ KPKAL 96_ QHTES 101_ PSETN 106_ KPHSK 111_ SKKRH 116_ LDQEQ 121_ QLKSA 126_ QSPST 131_ SKAHT 136_ RKSGA 141_ TGGSR 146_ SQKRK 151_ RTESS 156_ CVKSG 161_ SGSES 166_ TGAEE 171_ RSAKP 176_ TKLAS 181_ KSATS 186_ AKAGC 191_ STITD 196_ SSSAA 201_ STSSS 206_ SSAVA 211_ SASST 216_ VPPGA 221_ RVKQG 226_ KDQNK 231_ ARRSR 236_ SASSP 241_ SPRRS 246_ SREKE 251_ QSKTG 256_ GSSKF 261_ DWAAR 266_ FSPKV 271_ SLPKT 276_ KLSLP 281_ GSSKS 286_ ETSKP 291_ GPSGL 296_ QAKLA 301_ SLRKS 306_ TKKRS 311_ ESPPA 316_ ELPSL 321_ RRSTR 326_ QKTTG 331_ SCAST 336_ SRRGS 341_ GLGKR 346_ GAAEA 351_ RRQEK 356_ MADPE 361_ SNQEA 366_ VNSSA 371_ ARTDE 376_ APQGA 381_ AGAVG 386_ MTTSG 391_ ESESD 396_ DSEMG 401_ RLQAL 406_ LEARG 411_ LPPHL 416_ FGPLG 421_ PRMSQ 426_ LFHRT 431_ IGSGA 436_ SSKAQ 441_ QLLQG 446_ LQASD 451_ ESQQL 456_ QAVIE 461_ MCQLL 466_ VMGNE 471_ ETLGG 476_ FPVKS 481_ VVPAL 486_ ITLLQ 491_ MEHNF 496_ DIMNH 501_ ACRAL 506_ TYMME 511_ ALPRS 516_ SAVVV 521_ DAIPV 526_ FLEKL 531_ QVIQC 536_ IDVAE 541_ QALTA 546_ LEMLS 551_ RRHSK 556_ AILQA 561_ GGLAD 566_ CLLYL 571_ EFFSI 576_ NAQRN 581_ ALAIA 586_ ANCCQ 591_ SITPD 596_ EFHFV 601_ ADSLP 606_ LLTQR 611_ LTHQD 616_ KKSVE 621_ STCLC 626_ FARLV 631_ DNFQH 636_ EENLL 641_ QQVAS 646_ KDLLT 651_ NVQQL 656_ LVVTP 661_ PILSS 666_ GMFIM 671_ VVRMF 676_ SLMCS 681_ NCPTL 686_ AVQLM 691_ KQNIA 696_ ETLHF 701_ LLCGA 706_ SNGSC 711_ QEQID 716_ LVPRS 721_ PQELY 726_ ELTSL 731_ ICELM 736_ PCLPK 741_ EGIFA 746_ VDTML 751_ KKGNA 756_ QNTDG 761_ AIWQW 766_ RDDRG 771_ LWHPY 776_ NRIDS 781_ RIIEQ 786_ INEDT 791_ GTARA 796_ IQRKP 801_ NPLAN 806_ SNTSG 811_ YSESK 816_ KDDAR 821_ AQLMK 826_ EDPEL 831_ AKSFI 836_ KTLFG 841_ VLYEV 846_ YSSSA 851_ GPAVR 856_ HKCLR 861_ AILRI 866_ IYFAD 871_ AELLK 876_ DVLKN 881_ HAVSS 886_ HIASM 891_ LSSQD 896_ LKIVV 901_ GALQM 906_ AEILM 911_ QKLPD 916_ IFSVY 921_ FRREG 926_ VMHQV 931_ KHLAE 936_ SESLL 941_ TSPPK 946_ ACTNG 951_ SGSMG 956_ STTSV 961_ SSGTA 966_ TAATH 971_ AAADL 976_ GSPSL 981_ QHSRD 986_ DSLDL 991_ SPQGR 996_ LSDVL 1001_ KRKRL 1006_ PKRGP 1011_ RRPKY 1016_ SPPRD 1021_ DDKVD 1026_ NQAKS 1031_ PTTTQ 1036_ SPKSS 1041_ FLASL 1046_ NPKTW 1051_ GRLST 1056_ QSNSN 1061_ NIEPA 1066_ RTAGG 1071_ SGLAR 1076_ AASKD 1081_ TISNN 1086_ REKIK 1091_ GWIKE 1096_ QAHKF 1101_ VERYF 1106_ SSENM 1111_ DGSNP 1116_ ALNVL 1121_ QRLCA 1126_ ATEQL 1131_ NLQVD 1136_ GGAEC 1141_ LVEIR 1146_ SIVSE 1151_ SDVSS 1156_ FEIQH 1161_ SGFVK 1166_ QLLLY 1171_ LTSKS 1176_ EKDAV 1181_ SREIR 1186_ LKRFL 1191_ HVFFS 1196_ SPLPG 1201_ EEPIG 1206_ RVEPV 1211_ GNAPL 1216_ LALVH 1221_ KMNNC 1226_ LSQME 1231_ QFPVK 1236_ VHDFP 1241_ SGNGT 1246_ GGSFS 1251_ LNRGS 1256_ QALKF 1261_ FNTHQ 1266_ LKCQL 1271_ QRHPD 1276_ CANVK 1281_ QWKGG 1286_ PVKID 1291_ PLALV 1296_ QAIER 1301_ YLVVR 1306_ GYGRV 1311_ REDDE 1316_ DSDDD 1321_ GSDEE 1326_ IDESL 1331_ AAQFL 1336_ NSGNV 1341_ RHRLQ 1346_ FYIGE 1351_ HLLPY 1356_ NMTVY 1361_ QAVRQ 1366_ FSIQA 1371_ EDERE 1376_ STDDE 1381_ SNPLG 1386_ RAGIW 1391_ TKTHT 1396_ IWYKP 1401_ VREDE 1406_ ESNKD 1411_ CVGGK 1416_ RGRAQ 1421_ TAPTK 1426_ TSPRN 1431_ AKKHD 1436_ ELWHD 1441_ GVCPS 1446_ VSNPL 1451_ EVYLI 1456_ PTPPE 1461_ NITFE 1466_ DPSLD 1471_ VILLL 1476_ RVLHA 1481_ ISRYW 1486_ YYLYD 1491_ NAMCK 1496_ EIIPT 1501_ SEFIN 1506_ SKLTA 1511_ KANRQ 1516_ LQDPL 1521_ VIMTG 1526_ NIPTW 1531_ LTELG 1536_ KTCPF 1541_ FFPFD 1546_ TRQML 1551_ FYVTA 1556_ FDRDR 1561_ AMQRL 1566_ LDTNP 1571_ EINQS 1576_ DSQDS 1581_ RVAPR 1586_ LDRKK 1591_ RTVNR 1596_ EELLK 1601_ QAESV 1606_ MQDLG 1611_ SSRAM 1616_ LEIQY 1621_ ENEVG 1626_ TGLGP 1631_ TLEFY 1636_ ALVSQ 1641_ ELQRA 1646_ DLGLW 1651_ RGEEV 1656_ TLSNP 1661_ KGSQE 1666_ GTKYI 1671_ QNLQG 1676_ LFALP 1681_ FGRTA 1686_ KPAHI 1691_ AKVKM 1696_ KFRFL 1701_ GKLMA 1706_ KAIMD 1711_ FRLVD 1716_ LPLGL 1721_ PFYKW 1726_ MLRQE 1731_ TSLTS 1736_ HDLFD 1741_ IDPVV 1746_ ARSVY 1751_ HLEDI 1756_ VRQKK 1761_ RLEQD 1766_ KSQTK 1771_ ESLQY 1776_ ALETL 1781_ TMNGC 1786_ SVEDL 1791_ GLDFT 1796_ LPGFP 1801_ NIELK 1806_ KGGKD 1811_ IPVTI 1816_ HNLEE 1821_ YLRLV 1826_ IFWAL 1831_ NEGVS 1836_ RQFDS 1841_ FRDGF 1846_ ESVFP 1851_ LSHLQ 1856_ YFYPE 1861_ ELDQL 1866_ LCGSK 1871_ ADTWD 1876_ AKTLM 1881_ ECCRP 1886_ DHGYT 1891_ HDSRA 1896_ VKFLF 1901_ EILSS 1906_ FDNEQ 1911_ QRLFL 1916_ QFVTG 1921_ SPRLP 1926_ VGGFR 1931_ SLNPP 1936_ LTIVR 1941_ KTFES 1946_ TENPD 1951_ DFLPS 1956_ VMTCV 1961_ NYLKL 1966_ PDYSS 1971_ IEIMR 1976_ EKLLI 1981_ AAREG 1986_QQSFH
1: E3 ubiquitin-protein ligase involved in ubiquitin fusion degradation (UFD) pathway and regulation of DNA repair (PubMed:19028681, PubMed:22884692). Part of the ubiquitin fusion degradation (UFD) pathway, a process that mediates ubiquitination of protein at their N-terminus, regardless of the presence of lysine residues in target proteins (PubMed:19028681). Acts as a key regulator of DNA damage response by acting as a suppressor of RNF168, an E3 ubiquitin-protein ligase that promotes accumulation of 'Lys-63'-linked histone H2A and H2AX at DNA damage sites, thereby acting as a guard against excessive spreading of ubiquitinated chromatin at damaged chromosomes (PubMed:22884692). In normal cells, mediates ubiquitination and degradation of isoform p19ARF/ARF of CDKN2A, a lysine-less tumor suppressor required for p53/TP53 activation under oncogenic stress (PubMed:20208519). In cancer cells, however, isoform p19ARF/ARF and TRIP12 are located in different cell compartments, preventing isoform p19ARF/ARF ubiquitination and degradation (PubMed:20208519). Does not mediate ubiquitination of isoform p16-INK4a of CDKN2A (PubMed:20208519). Also catalyzes ubiquitination of NAE1 and SMARCE1, leading to their degradation (PubMed:18627766). Ubiquitination and degradation of target proteins is regulated by interaction with proteins such as MYC, TRADD or SMARCC1, which disrupt the interaction between TRIP12 and target proteins (PubMed:20829358). Mediates ubiquitination of ASXL1: following binding to N(6)-methyladenosine methylated DNA, ASXL1 is ubiquitinated by TRIP12, leading to its degradation and subsequent inactivation of the PR-DUB complex (PubMed:30982744)